Related references
Note: Only part of the references are listed.Interleukin-6 receptor blockade with subcutaneous tocilizumab in severe COVID-19 pneumonia and hyperinflammation: a case-control study
Nicola Potere et al.
ANNALS OF THE RHEUMATIC DISEASES (2021)
Rationale and evidence on the use of tocilizumab in COVID-19: a systematic review
A. Cortegiani et al.
PULMONOLOGY (2021)
Tocilizumab shortens time on mechanical ventilation and length of hospital stay in patients with severe COVID-19: a retrospective cohort study
J. Eimer et al.
JOURNAL OF INTERNAL MEDICINE (2021)
T-cell responses and therapies against SARS-CoV-2 infection
Salman M. Toor et al.
IMMUNOLOGY (2021)
Tocilizumab use in COVID-19-associated pneumonia
Alexis K. Okoh et al.
JOURNAL OF MEDICAL VIROLOGY (2021)
Association Between Early Treatment With Tocilizumab and Mortality Among Critically Ill Patients With COVID-19
Shruti Gupta et al.
JAMA INTERNAL MEDICINE (2021)
Effect of Tocilizumab vs Usual Care in Adults Hospitalized With COVID-19 and Moderate or Severe Pneumonia A Randomized Clinical Trial
Olivier Hermine et al.
JAMA INTERNAL MEDICINE (2021)
Tocilizumab in Patients Hospitalized with Covid-19 Pneumonia
Carlos Salama et al.
NEW ENGLAND JOURNAL OF MEDICINE (2021)
Interleukin-6 Receptor Inhibition in Covid-19-Cooling the Inflammatory Soup
Eric J. Rubin et al.
NEW ENGLAND JOURNAL OF MEDICINE (2021)
Tocilizumab in Hospitalized Patients with Severe Covid-19 Pneumonia
I. O. Rosas et al.
NEW ENGLAND JOURNAL OF MEDICINE (2021)
Immunopathogenesis and treatment of cytokine storm in COVID-19
Jae Seok Kim et al.
THERANOSTICS (2021)
Coronavirus infections and immune responses
Geng Li et al.
JOURNAL OF MEDICAL VIROLOGY (2020)
Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China
Chaolin Huang et al.
LANCET (2020)
A pneumonia outbreak associated with a new coronavirus of probable bat origin
Peng Zhou et al.
NATURE (2020)
Immune response to SARS-CoV-2 and mechanisms of immunopathological changes in COVID-19
Ahmet Kursat Azkur et al.
ALLERGY (2020)
Tocilizumab for the treatment of severe COVID-19 pneumonia with hyperinflammatory syndrome and acute respiratory failure: A single center study of 100 patients in Brescia, Italy
Paola Toniati et al.
AUTOIMMUNITY REVIEWS (2020)
SARS-CoV-2 Cell Entry Depends on ACE2 and TMPRSS2 and Is Blocked by a Clinically Proven Protease Inhibitor
Markus Hoffmann et al.
CELL (2020)
Functional exhaustion of antiviral lymphocytes in COVID-19 patients
Meijuan Zheng et al.
CELLULAR & MOLECULAR IMMUNOLOGY (2020)
Rational Use of Tocilizumab in the Treatment of Novel Coronavirus Pneumonia
Shengyu Zhang et al.
CLINICAL DRUG INVESTIGATION (2020)
Dysregulation of Immune Response in Patients With Coronavirus 2019 (COVID-19) in Wuhan, China
Chuan Qin et al.
CLINICAL INFECTIOUS DISEASES (2020)
Efficacy and safety of tocilizumab in severe COVID-19 patients: a single-centre retrospective cohort study
Corrado Campochiaro et al.
EUROPEAN JOURNAL OF INTERNAL MEDICINE (2020)
Cytokine release syndrome in severe COVID-19: interleukin-6 receptor antagonist tocilizumab may be the key to reduce mortality
Chi Zhang et al.
INTERNATIONAL JOURNAL OF ANTIMICROBIAL AGENTS (2020)
Effective treatment of severe COVID-19 patients with tocilizumab
Xiaoling Xu et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2020)
TH17 responses in cytokine storm of COVID-19: An emerging target of JAK2 inhibitor Fedratinib
Dandan Wu et al.
JOURNAL OF MICROBIOLOGY IMMUNOLOGY AND INFECTION (2020)
Why the immune system fails to mount an adaptive immune response to a COVID-19 infection
Pedram Ahmadpoor et al.
TRANSPLANT INTERNATIONAL (2020)
Virology, Epidemiology, Pathogenesis, and Control of COVID-19
Yuefei Jin et al.
VIRUSES-BASEL (2020)
SARS-CoV-2 infection and overactivation of Nlrp3 inflammasome as a trigger of cytokine storm and risk factor for damage of hematopoietic stem cells
Mariusz Z. Ratajczak et al.
LEUKEMIA (2020)
Reduction and Functional Exhaustion of T Cells in Patients With Coronavirus Disease 2019 (COVID-19)
Bo Diao et al.
FRONTIERS IN IMMUNOLOGY (2020)
Pathogenic T-cells and inflammatory monocytes incite inflammatory storms in severe COVID-19 patients
Yonggang Zhou et al.
NATIONAL SCIENCE REVIEW (2020)
New therapeutic opportunities for COVID-19 patients with Tocilizumab: Possible correlation of interleukin-6 receptor inhibitors with osteonecrosis of the jaws
Francesco Bennardo et al.
ORAL ONCOLOGY (2020)
Tocilizumab Treatment for Cytokine Release Syndrome in Hospitalized Patients With Coronavirus Disease 2019 Survival and Clinical Outcomes
Christina C. Price et al.
CHEST (2020)
The Role of Cytokines including Interleukin-6 in COVID-19 induced Pneumonia and Macrophage Activation Syndrome-Like Disease
Dennis McGonagle et al.
AUTOIMMUNITY REVIEWS (2020)
Tocilizumab for severe COVID-19: a systematic review and meta-analysis
Shao-Huan Lan et al.
INTERNATIONAL JOURNAL OF ANTIMICROBIAL AGENTS (2020)
The COVID-19 Cytokine Storm; What We Know So Far
Dina Ragab et al.
FRONTIERS IN IMMUNOLOGY (2020)
nCOVID-19 Pandemic: From Molecular Pathogenesis to Potential Investigational Therapeutics
Md Tanvir Kabir et al.
FRONTIERS IN CELL AND DEVELOPMENTAL BIOLOGY (2020)
A Case for Targeting Th17 Cells and IL-17A in SARS-CoV-2 Infections
Marika Orlov et al.
JOURNAL OF IMMUNOLOGY (2020)
The pathogenesis and treatment of the 'Cytokine Storm' in COVID-19
Qing Ye et al.
JOURNAL OF INFECTION (2020)
Cytokine storm induced by SARS-CoV-2
Peipei Song et al.
CLINICA CHIMICA ACTA (2020)
Marked T cell activation, senescence, exhaustion and skewing towards TH17 in patients with COVID-19 pneumonia
Sara De Biasi et al.
NATURE COMMUNICATIONS (2020)
Beneficial effect of corticosteroids in preventing mortality in patients receiving tocilizumab to treat severe COVID-19 illness
Manuel Rubio-Rivas et al.
INTERNATIONAL JOURNAL OF INFECTIOUS DISEASES (2020)
Tocilizumab for patients with COVID-19 pneumonia. The single-arm TOCIVID-19 prospective trial
Francesco Perrone et al.
JOURNAL OF TRANSLATIONAL MEDICINE (2020)
COVID-19 vaccine BNT162b1 elicits human antibody and TH1 T cell responses
Ugur Sahin et al.
NATURE (2020)
Broad and strong memory CD4+and CD8+T cells induced by SARS-CoV-2 in UK convalescent individuals following COVID-19
Yanchun Peng et al.
NATURE IMMUNOLOGY (2020)
Efficacy of Tocilizumab in Patients Hospitalized with Covid-19
John H. Stone et al.
NEW ENGLAND JOURNAL OF MEDICINE (2020)
Lung under attack by COVID-19-induced cytokine storm: pathogenic mechanisms and therapeutic implications
Corrado Pelaia et al.
THERAPEUTIC ADVANCES IN RESPIRATORY DISEASE (2020)
The trinity of COVID-19: immunity, inflammation and intervention
Matthew Zirui Tay et al.
NATURE REVIEWS IMMUNOLOGY (2020)
TGF-β pathway activation by idiopathic pulmonary fibrosis (IPF) fibroblast derived soluble factors is mediated by IL-6 trans-signaling
Gali Epstein Shochet et al.
RESPIRATORY RESEARCH (2020)
The origin, transmission and clinical therapies on coronavirus disease 2019 (COVID-19) outbreak - an update on the status
Yan-Rong Guo et al.
MILITARY MEDICAL RESEARCH (2020)
Oxygen therapy via high flow nasal cannula in severe respiratory failure caused by Sars-Cov-2 infection: a real-life observational study
Giada Procopio et al.
THERAPEUTIC ADVANCES IN RESPIRATORY DISEASE (2020)
COVID-19: what has been learned and to be learned about the novel coronavirus disease
Ye Yi et al.
INTERNATIONAL JOURNAL OF BIOLOGICAL SCIENCES (2020)
A tug-of-war between severe acute respiratory syndrome coronavirus 2 and host antiviral defence: lessons from other pathogenic viruses
Sin-Yee Fung et al.
EMERGING MICROBES & INFECTIONS (2020)
The Role of Interleukin 6 During Viral Infections
Lauro Velazquez-Salinas et al.
FRONTIERS IN MICROBIOLOGY (2019)
The balance of interleukin (IL)-6, IL-6•soluble IL-6 receptor (sIL-6R), and IL-6•sIL-6R•sgp130 complexes allows simultaneous classic and trans-signaling
Paul Baran et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2018)
Interleukin-6: designing specific therapeutics for a complex cytokine
Christoph Garbers et al.
NATURE REVIEWS DRUG DISCOVERY (2018)
Trans-presentation of IL-6 by dendritic cells is required for the priming of pathogenic TH17 cells
Sylvia Heink et al.
NATURE IMMUNOLOGY (2017)
Pathogenic human coronavirus infections: causes and consequences of cytokine storm and immunopathology
Rudragouda Channappanavar et al.
SEMINARS IN IMMUNOPATHOLOGY (2017)
Tocilizumab (Actemra)
Martin Sheppard et al.
HUMAN VACCINES & IMMUNOTHERAPEUTICS (2017)
Proteolytic Origin of the Soluble Human IL-6R In Vivo and a Decisive Role of N-Glycosylation
Steffen Riethmueller et al.
PLOS BIOLOGY (2017)
Tocilizumab: A Review in Rheumatoid Arthritis
Lesley J. Scott
DRUGS (2017)
Tocilizumab as an Adjuvant Therapy for Hemophagocytic Lymphohistiocytosis Associated With Visceral Leishmaniasis
Raquel Rios-Fernandez et al.
AMERICAN JOURNAL OF THERAPEUTICS (2016)
IL-6 pathway in the liver: From physiopathology to therapy
Dirk Schmidt-Arras et al.
JOURNAL OF HEPATOLOGY (2016)
Interleukin-6: Biology, signaling and strategies of blockade
Fred Schaper et al.
CYTOKINE & GROWTH FACTOR REVIEWS (2015)
Tocilizumab in rheumatoid arthritis: A meta-analysis of efficacy and selected clinical conundrums
Geraldine Navarro et al.
SEMINARS IN ARTHRITIS AND RHEUMATISM (2014)
Therapeutic Targeting of the Interleukin-6 Receptor
Toshio Tanaka et al.
ANNUAL REVIEW OF PHARMACOLOGY AND TOXICOLOGY, VOL 52 (2012)
Plasticity and cross-talk of Interleukin 6-type cytokines
Christoph Garbers et al.
CYTOKINE & GROWTH FACTOR REVIEWS (2012)
IL-6 Trans-Signaling via the Soluble IL-6 Receptor: Importance for the Pro-Inflammatory Activities of IL-6
Stefan Rose-John
INTERNATIONAL JOURNAL OF BIOLOGICAL SCIENCES (2012)
The pro- and anti-inflammatory properties of the cytokine interleukin-6
Juergen Scheller et al.
BIOCHIMICA ET BIOPHYSICA ACTA-MOLECULAR CELL RESEARCH (2011)
IL-6: from its discovery to clinical applications
Tadamitsu Kishimoto
INTERNATIONAL IMMUNOLOGY (2010)
Cooperation of Tim-3 and PD-1 in CD8 T-cell exhaustion during chronic viral infection
Hyun-Tak Jin et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2010)
Revisiting Immune Exhaustion During HIV Infection
Alka Khaitan et al.
Current HIV/AIDS Reports (2010)
Tocilizumab A Review of its Use in the Management of Rheumatoid Arthritis
Vicki Oldfield et al.
DRUGS (2009)
Severe Acute Respiratory Syndrome (SARS) Coronavirus-Induced Lung Epithelial Cytokines Exacerbate SARS Pathogenesis by Modulating Intrinsic Functions of Monocyte-Derived Macrophages and Dendritic Cells
Tomoki Yoshikawa et al.
JOURNAL OF VIROLOGY (2009)
Cytokine regulation in SARS coronavirus infection compared to other respiratory virus infections
T Okabayashi et al.
JOURNAL OF MEDICAL VIROLOGY (2006)
Role of vascular cell adhesion molecules and leukocyte apoptosis in the lymphopenia and thrombocytopenia of patients with severe acute respiratory syndrome (SARS)
RF Chen et al.
MICROBES AND INFECTION (2006)
Characterization of cytokine/chemokine profiles of severe acute respiratory syndrome
Y Jiang et al.
AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE (2005)
Apoptosis, pyroptosis, and necrosis: Mechanistic description of dead and dying eukaryotic cells
SL Fink et al.
INFECTION AND IMMUNITY (2005)
Analysis of serum cytokines in patients with severe acute respiratory syndrome
YC Zhang et al.
INFECTION AND IMMUNITY (2004)
Molecular mechanisms of corticosteroid actions in chronic inflammatory airway diseases
G Pelaia et al.
LIFE SCIENCES (2003)
Share Paper
